Observational Study of Intranasal IVIG and RXRA Gene Expression in Long COVID Patients Undergoing Medical Tourism

Launched by HEALING HOPE INTERNATIONAL · May 23, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a treatment called intranasal immunoglobulin (IVIG) might help people suffering from Long COVID, especially those with weakened immune systems. Long COVID can cause ongoing symptoms like fatigue, brain fog, and inflammation, and this study aims to gather information about these symptoms and their connection to a specific gene called RXRA, which is involved in managing inflammation and immune responses. The study is observational, meaning that participants will not receive any new treatments; instead, researchers will collect health information and lab results to better understand the potential benefits of IVIG therapy.

To be eligible for this study, participants need to be between 18 and 65 years old, have been diagnosed with Long COVID for at least 12 weeks after their COVID-19 infection, and show signs of immunodeficiency, such as low levels of certain antibodies. They should also be free from active infections and not currently on medications that suppress the immune system. Throughout the study, participants will undergo genetic testing to see how the RXRA gene might relate to their recovery or ongoing symptoms. It’s important to know that all data collected will be kept confidential and used to improve understanding and treatment options for Long COVID in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 to 65 years
• • Clinical diagnosis of Long COVID (symptoms persisting ≥12 weeks after SARS-CoV-2 infection)
• Laboratory-confirmed immunodeficiency, including one or more of the following:
• • Low serum IgG and/or IgA
• • Specific antibody deficiency
• • Low pneumonia titers
• • Elevated inflammatory markers (e.g., CRP, cytokines)
• • No active infections at the time of enrollment (bacterial, viral, or fungal)
• • Negative for Lyme disease and NMDAR antibodies
• • Willingness to provide informed consent for data collection and use
• Exclusion Criteria:
• • 1. Current or recent active infection (e.g., viral, bacterial, or fungal)
• • 2. Use of immunosuppressive therapy within the last 3 months
• • 3. Active Infections: Participants with active infections, including viral, bacterial, or fungal infections, will be excluded.
• • 4. Neurological Disorders: Participants with diagnosed neurological disorders, such as multiple sclerosis, Parkinson's disease, or Alzheimer's disease, will be excluded.
• • 5. Immunosuppressive Therapy: Participants receiving immunosuppressive therapy will be excluded.
• • 6. Inability to comply with study assessments or procedures